CXCL13 and in situ carcinoma: A more recent study including patients with the radiologically isolated syndrome (RIS), CIS, RRMS, and progressive MS found that CSF/serum CXCL13 may serve as a single predictor in MS; indeed CXCL13 can be considered even more sensitive, specific, and predictive than more well-known OCB and NfL (DiSano et al., 2020).